רדאר קליני AI | ||
|---|---|---|
הניסוי הקליני NCT07492524 עבור פרפור פרוזדורים, אי ספיקת לב הוא טרם החל גיוס. לכל הפרטים, עיינו בתצוגת הכרטיסים של רדאר ניסויים קליניים ובכלי הגילוי של AI. אפשר גם לשאול כל דבר כאן. | ||
מחקר אחד תואם לקריטריוני המסנן
תצוגת כרטיסים
Telemedicine-based Integrated Management of Atrial Fibrillation and Heart Failure in Older Patients in Village Clinics 1,227 אקראי בריאות דיגיטלית מכשיר לביש אורח חיים
פרטי הניסויים הקליניים זמינים בעיקר באנגלית. רדאר קליני AI יכול לעזור! לחץ על 'הסבר את המחקר' כדי לצפות ולשוחח על מידע מהמחקר בשפה המועדפת עליך.
הניסוי הקליני NCT07492524 הוא מחקר מסוג התערבותי עבור פרפור פרוזדורים, אי ספיקת לב, שנמצא במצב טרם החל גיוס. גיוס המשתתפים צפוי להתחיל ב-25 במרץ 2026, במטרה לכלול 1,227 משתתפים. המחקר ינוהל על ידי Jiangsu Taizhou People's Hospital וצפוי להסתיים ב-1 באפריל 2029. מידע זה עודכן לאחרונה באתר ClinicalTrials.gov ב-25 במרץ 2026.
סיכום קצר
The goal of this cluster-randomized clinical trial is to evaluate a telemedicine-based, village doctor-led integrated management program for older adults (aged 65-80 years) who have both atrial fibrillation (AF) and heart failure (HF) in rural clinics in China. It aims to answer whether the digitally-supported program improves heart failure prognosis, assessed by the MAGGIC score, at 12 months , and reduces the risk ...הצג עוד
תיאור מפורט
Atrial fibrillation (AF) and heart failure (HF) frequently coexist and mutually reinforce one another, forming a "vicious cycle" that is particularly destructive in older adults. Older patients with AF are at high risk for HF progression, and AF-HF comorbidity is a central determinant of long-term prognosis. In rural China, effective prevention and long-term management face practical bottlenecks, including inadequate...הצג עוד
כותרת רשמית
Telemedicine-based Integrated Management of Atrial Fibrillation and Heart Failure in Older Patients in Village Clinics: the MIRACLE-AF II Cluster Randomized Trial
מצבים רפואיים
פרפור פרוזדוריםאי ספיקת לבמזהי מחקר נוספים
- LSKY 2025-192-01
מספר NCT
תחילת המחקר (בפועל)
2026-03-25
עדכון אחרון שפורסם
2026-03-25
סיום המחקר (מוערך)
2029-04-01
משתתפים (מתוכנן)
1,227
סוג המחקר
התערבותי
שלב
לא ישים
סטטוס
טרם החל גיוס
מטרה ראשית
טיפול
הקצאת טיפול
אקראי
דגם מתערב
קבוצות מקבילות
עיוורון
אין (מחקר פתוח)
זרועות / התערבויות
| קבוצת משתתפים/זרוע | התערבות/טיפול |
|---|---|
ניסיDigital Intelligent Integrated Management Group Participants receive village doctor-led integrated management supported by digital technology. This includes a digital health platform for intelligent decision-making, remote specialist support, and structured multidimensional lifestyle interventions (cardiac rehabilitation, smart wearable device monitoring, and personalized health education) | Digital Intelligent Integrated Management This multi-component intervention includes:
1. A digital chronic disease management system for AF screening and intelligent decision-making.
2. Structured multidimensional lifestyle intervention featuring monthly peer-support group cardiac rehabilitation (aerobic, resistance, and flexibility training).
3. Smart wearable device monitoring (HUAWEI Band 6) for heart rate and step counts.
4. Personalized health educatio...הצג עוד |
משווה פעילConventional Management Group Participants receive standard diagnosis and treatment for common chronic diseases (hypertension, diabetes, and COPD) and Basic Public Health Services (BPHS) provided by primary care physicians according to national specifications. | ניהול קונבנציונלי Participants in the control group receive standard diagnosis and treatment for common chronic diseases (hypertension, diabetes, and chronic obstructive pulmonary disease) and Basic Public Health Services (BPHS) provided by primary care physicians. The 14 government-provided BPHS items primarily include quarterly follow-up visits for patients with hypertension, diabetes, and COPD, an annual free physical examination f...הצג עוד |
מדדי תוצאה ראשיים
מדדי תוצאה משניים
| מדד תוצאה | תיאור המדידה | טווח זמן |
|---|---|---|
Change in Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) Risk Score | Risk stratification is performed using the MAGGIC risk score, a validated integer scoring system that integrates 13 key predictors: age, gender, NYHA classification, left ventricular ejection fraction (LVEF), smoking status, diabetes, COPD, heart failure diagnosed within the past 18 months, systolic blood pressure (SBP), body mass index (BMI), serum creatinine level, use of beta-blockers, and use of ACEI/ARB. The cumulative score ranges from 0 to 50. Higher scores indicate a higher risk of mortality and a worse prognosis. | Baseline to 12 months |
Number of Participants Experiencing a Composite Cardiovascular Endpoint | This is a composite endpoint tracking the first occurrence of any of the following events: cardiovascular death, ischemic or hemorrhagic stroke, hospitalization due to worsening heart failure (HF) or acute coronary syndrome (ACS), and emergency visits for atrial fibrillation (AF). | Up to 36 months |
| מדד תוצאה | תיאור המדידה | טווח זמן |
|---|---|---|
Number of Participants with Cardiovascular Death at 12 Months | Incidence of cardiovascular death, defined as death due to acute myocardial infarction, heart failure, cardiac arrhythmia, cardiac perforation, cardiac tamponade, or other cardiogenic causes. Deaths caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism are also classified as cardiovascular deaths | Up to 12 months |
Number of Participants with Cardiovascular-Related Hospitalization at 12 Months | Incidence of hospitalization in township-level or higher hospitals caused by cardiovascular diseases (sudden cardiac death, heart failure, cardiac arrhythmia, acute coronary syndrome, hypertensive emergency or hypertensive subemergency, etc.) or neurological diseases (ischemic or hemorrhagic stroke, transient ischemic attack) | Up to 12 months |
Number of Participants with Emergency Visits for Cardiovascular Events at 12 Months | Incidence of emergency visits for cardiovascular events, including exacerbation of heart failure or acute coronary syndrome. | Up to 12 months |
Number of Participants with Stroke at 12 Months | Incidence of stroke, defined as a new onset of neurological deficit symptoms or signs with a duration of at least 24 hours, caused by the sudden rupture of cerebral blood vessels or insufficient cerebral blood perfusion due to vascular occlusion, which is confirmed by cranial CT/MRI evidence or diagnosed by a neurological expert group. | Up to 12 months |
Number of Participants with Cardiovascular Death at 36 Months | Incidence of cardiovascular death, defined as death due to acute myocardial infarction, heart failure, cardiac arrhythmia, cardiac perforation, cardiac tamponade, or other cardiogenic causes. Deaths caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism are also classified as cardiovascular deaths | Up to 36 months |
Number of Participants with Cardiovascular-Related Hospitalization at 36 Months | Incidence of hospitalization in township-level or higher hospitals caused by cardiovascular diseases (sudden cardiac death, heart failure, cardiac arrhythmia, acute coronary syndrome, hypertensive emergency or hypertensive subemergency, etc.) or neurological diseases (ischemic or hemorrhagic stroke, transient ischemic attack). | Up to 36 months |
Number of Participants with Emergency Visits for Cardiovascular Events at 36 Months | Incidence of emergency visits for cardiovascular events, including exacerbation of heart failure or acute coronary syndrome. | Up to 36 months |
Number of Participants with Stroke at 36 Months | Incidence of stroke, defined as a new onset of neurological deficit symptoms or signs with a duration of at least 24 hours, caused by the sudden rupture of cerebral blood vessels or insufficient cerebral blood perfusion due to vascular occlusion, which is confirmed by cranial CT/MRI evidence or diagnosed by a neurological expert group. | Up to 36 months |
Change in Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) Risk Score at 36 Months | Risk stratification will be performed using the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) risk score. This validated integer scoring system integrates 13 key predictors to calculate a cumulative risk score ranging from 0 to 50. Higher scores indicate a worse prognosis. | Baseline and 36 months |
עוזר השתתפות
קריטריוני זכאות
גילאים מוערכים למחקר
גיל שלישי
גיל מינימלי למחקר
65 Years
מגדרים מוערכים למחקר
הכל
- Permanent residents with local household registration at the primary level in Jiangsu Province, aged 65-80 years.
- Electrocardiogram (ECG) confirmation of AF or possession of a diagnostic certificate for AF issued by a specialist.
- A documented history of HF or a diagnosis of HF based on echocardiography and/or NT-proBNP screening, defined by the presence of typical HF symptoms and/or signs, together with one of the following: reduced left ventricular ejection fraction (HFrEF; LVEF < 40%), mildly reduced left ventricular ejection fraction (HFmrEF; LVEF 40-49%), or preserved left ventricular ejection fraction with elevated NT-proBNP and structural heart disease changes (HFpEF; LVEF ≥ 50%, meeting at least one of the following criteria: LAV 40 ml/m², E/e' ≥ 15, or TRV > 2.8 m/s).
- Management by a village clinic near the participant's place of residence.
- Ability to understand the study procedures and provide written informed consent.
- Expected life expectancy of less than 3 months.
- Severe renal insufficiency (Ccr < 30ml/min) or ongoing dialysis treatment.
- Cardiac insufficiency secondary to correctable causes, including hyperthyroid heart disease, anemic heart disease, or uncorrected congenital heart disease.
- Indications for pacemaker implantation without having undergone implantation.
- Chronic obstructive pulmonary disease (COPD) complicated by type II respiratory failure.
- Special populations, including patients with mental illnesses.
Jiangsu Taizhou People's Hospitalהגורם האחראי למחקר
Ming Chu, חוקר ראשי, Chief Physician, Jiangsu Taizhou People's Hospital
אין נתוני קשר.